Moreover, metastases account for >70% of deaths of the patients with advanced-stage NSCLC 5, and brain metastasis (BMs) occurs in approximately 33% of the patients with EGFR mutation 6. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.